Pharsight

Durysta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8629185 ABBVIE 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof
Jul, 2031

(7 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7033605 ABBVIE Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
Oct, 2020

(3 years ago)

US10398707 ABBVIE Hypotensive lipid-containing biodegradable intraocular implants and related implants
Apr, 2024

(a month ago)

US8673341 ABBVIE Intraocular pressure reduction with intracameral bimatoprost implants
Feb, 2025

(8 months from now)

US9149428 ABBVIE Processes for making cyclic lipid implants for intraocular use
Dec, 2026

(2 years from now)

US10441543 ABBVIE Processes for making cyclic lipid implants for intraocular use
Dec, 2026

(2 years from now)

US8206737 ABBVIE Hypotensive lipid-containing biodegradable intraocular implants and related methods
Apr, 2027

(2 years from now)

US7799336 ABBVIE Hypotensive lipid-containing biodegradable intraocular implants and related methods
Apr, 2029

(4 years from now)

US9492316 ABBVIE Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(10 years from now)

US9980974 ABBVIE Prostamide-containing intraocular implants and methods of use thereof
Oct, 2034

(10 years from now)

Durysta is owned by Abbvie.

Durysta contains Bimatoprost.

Durysta has a total of 10 drug patents out of which 2 drug patents have expired.

Expired drug patents of Durysta are:

  • US7033605
  • US10398707

Durysta was authorised for market use on 04 March, 2020.

Durysta is available in implant;ophthalmic dosage forms.

Durysta can be used as reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant.

The generics of Durysta are possible to be released after 31 October, 2034.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 04, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using BIMATOPROST ingredient

Market Authorisation Date: 04 March, 2020

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

More Information on Dosage

DURYSTA family patents

Family Patents